STOCK TITAN

VistaGen Therapeutics to Report 2021 Fiscal Year End Financial Results, Provide a Business Update and Host Conference Call and Webcast June 29, 2021

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

VistaGen Therapeutics (NASDAQ: VTGN) announced a corporate update conference call scheduled for June 29, 2021, at 2:00 PM PT. The call will disclose financial and operational results for the fiscal year ending March 31, 2021, and outline recent developments and future goals. CEO Shawn Singh will lead the call, which remains open to the public. A live audio webcast will also be accessible. This conference aims to inform shareholders and stakeholders about the company's progress in developing innovative treatments for CNS disorders.

Positive
  • None.
Negative
  • None.

SOUTH SAN FRANCISCO, Calif., June 25, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central nervous system (“CNS”) disorders, today announced that it will host a corporate update conference call on Tuesday, June 29, 2021 at 2:00 pm Pacific Time (5:00 pm Eastern Time) to discuss its financial and operating results for its fiscal year ended March 31, 2021 and provide a business update. 

Event: VistaGen Therapeutics 2021 Fiscal Year End Results and Business Update Conference Call
Date: Tuesday, June 29, 2021
Time: 2:00 pm PT (5:00 pm ET)
US Dial-in (Toll Free): 1-877-407-9716
TOLL/International Dial-in: 1-201-493-6779
Conference ID: 13720908

Shawn Singh, CEO of VistaGen, will host the call along with other members of the Company’s management team. The call is open to the public and will provide an update on recent developments, milestones during the Company’s 2021 fiscal year, which ended March 31, 2021, and certain target milestones and goals for future periods. 

A live audio webcast of the conference call will also be available via this link – http://public.viavid.com/index.php?id=145419.  Participants should access this webcast site 10 minutes before the start of the call. In addition, a telephone playback of the call will be available after approximately 5:00 pm PT on June 29, 2021. To listen to the replay, call toll free 1-844-512-2921 within the United States or 1-412-317-6671 when calling internationally (toll). Please use the replay PIN number 13720908.

About VistaGen
VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other CNS disorders. Each of VistaGen's three CNS drug candidates has a differentiated profile and therapeutic potential in multiple CNS markets. For more information, please visit www.VistaGen.com and connect with VistaGen on Twitter, LinkedIn, and Facebook.

VistaGen Company Contacts
Mark McPartland / Mark Flather
VistaGen Therapeutics
Phone: (650) 577-3606
Email: IR@vistagen.com


FAQ

What are the details of VistaGen's upcoming conference call on June 29, 2021?

The conference call will take place at 2:00 PM PT and will discuss financial results for the fiscal year ended March 31, 2021.

Who will host the VistaGen conference call on June 29, 2021?

The call will be hosted by CEO Shawn Singh along with other members of the management team.

How can I access the live webcast of the VistaGen conference call?

The live audio webcast can be accessed through VistaGen's investor relations page.

What topics will VistaGen cover during the conference call?

VistaGen will cover financial results, recent developments, and future milestones.

What is the significance of the fiscal year-end results for VistaGen?

The results will offer insights into VistaGen's financial performance and operational progress in developing CNS treatments.

Vistagen Therapeutics, Inc.

NASDAQ:VTGN

VTGN Rankings

VTGN Latest News

VTGN Stock Data

74.06M
27.77M
0.25%
53.61%
1.95%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SOUTH SAN FRANCISCO